29th week of 2010 patent applcation highlights part 34 |
Patent application number | Title | Published |
20100183660 | Cinnamomi and Poria Composition and Uses Thereof - A composition comprising Chinese herbal medicines | 2010-07-22 |
20100183661 | CHLORELLA EXTRACT-CONTAINING PRODUCT AND METHOD FOR IMPROVING THE STORAGE STABILITY OF THE SAME | 2010-07-22 |
20100183662 | VACCINE COMPRISING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CONJUGATES - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition is provided comprising a multivalent | 2010-07-22 |
20100183663 | INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA - The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives. | 2010-07-22 |
20100183664 | ATTENUATED RECOMBINANT NEWCASTLE DISEASE VIRUS AND VACCINE CONTAINING THE SAME - The present invention relates to a recombinant vector for transcription of the Newcastle disease virus (NDV) genome, a strain of attenuated recombinant NDV with a surface antigen of pathogenic NDV prepared by the vector, a method of preparing a recombinant NDV having low pathogenicity and high protectivity efficiency against Newcastle disease (ND) using the vector, and a vaccine against ND containing the recombinant NDV. | 2010-07-22 |
20100183665 | PROMOTERLESS CASSETTES FOR EXPRESSION OF ALPHA VIRUS STRUCTURAL PROTEINS - The present invention provides an isolated RNA molecule comprising: a) an alphavirus 5′ replication recognition sequence, wherein at least one initiation codon has been removed from the 5′ replication recognition sequence; b) a nucleotide sequence encoding an alphavirus structural protein; and c) an alphavirus 3′ replication recognition sequence, with the proviso that the RNA molecule does not contain a promoter that directs transcription of the nucleotide sequence of (b), and wherein the alphavirus 5′ and 3′ replication recognition sequences of (a) and (c) direct replication of the RNA molecule in the presence of alphavirus non-structural proteins. | 2010-07-22 |
20100183666 | METHODS OF REDUCING PAPILLOMAVIRUS INFECTION USING IMMUNOMODULATORY POLYNUCLEOTIDE SEQUENCES - The invention provides methods for the treatment of papillomavirus infections. A polynucleotide comprising an immunostimulatory sequence is administered to an individual who has been exposed to or infected by papillomavirus. The polynucleotide is not administered with papillomavirus antigen. Administration of the polynucleotide results in amelioration of symptoms of papillomavirus infection. | 2010-07-22 |
20100183667 | Vaccine Comprising an Oil in Water Emulsion Adjuvant - The present invention provides an immunogenic composition comprising an antigen or antigen composition and an adjuvant composition comprising an oil in water emulsion, wherein said oil in water emulsion comprises 0.5-10 mg metabolisable oil, 0.5-11 mg tocol and 0.1-4 mg emulsifying agent, per human dose. | 2010-07-22 |
20100183668 | USE OF COCCIDIAN - The present invention provides a novel use of coccidian, specifically relates to the use of coccidian as a vaccine live vector. The present invention further provides a live vaccine with coccidian as a vector, which is transgenic coccidian capable of expressing exogenous protein or stably transfected coccidian that contain expression vector and can express exogenous coccidian. The present coccidian vector live vaccine can induce organisms to simultaneously generate protective humoral and cellular immune responses (including the mucosal immune response), as well as generate memory responses, which can be readily carried out and has stable effect and high biological safety without generating immune tolerance. | 2010-07-22 |
20100183669 | Mannose immunogens for HIV-1 - Methods of producing a carbohydrate HIV vaccine or immunogenic composition are provided. One method comprises expressing a glycoprotein with a modified glycosylation, which facilitates binding of the glycoprotein to the 2G12 antibody. Another method comprises iteratively selecting cells with a high affinity for the 2G12 antibody. | 2010-07-22 |
20100183670 | METHOD FOR IDENTIFYING MOTIFS AND/OR COMBINATIONS OF MOTIFS HAVING A BOOLEAN STATE OF PREDETERMINED MUTATION IN A SET OF SEQUENCES AND ITS APPLICATION - A method for identifying a motif or a combination of motifs having a Boolean state of predetermined mutations in a set of sequences including a) aligning a set of sequences of ordered motifs represented by a single-character code, b) comparing a reference sequence with the set of sequences aligned in step (a), c) identifying motifs not having mutated simultaneously or motifs having mutated simultaneously at least once on at least one sequence of the set and not having mutated on another sequence of the set. | 2010-07-22 |
20100183671 | LOW-ADDITIVE INFLUENZA VACCINES - An influenza vaccine that lacks at least three of a mercurial preservative; an antibiotic; formaldehyde; and egg-derived materials. In some embodiments, the vaccine includes none of these four components. | 2010-07-22 |
20100183672 | PROCESS FOR PREPARING LIVE SMALLPOX VACCINE - A safer live smallpox vaccine, which contains a lowered content of revertants, is provided. A process for manufacturing a live smallpox vaccine which comprises steps of: inoculating a master seed solution of an attenuated vaccinia virus to an appropriate number of containers (1 to n wherein n is an integer) of rabbit kidney cells and incubating them; inoculating a portion of the cultured solution obtained from each container to RK-13 cells and to Vero E6 cells and incubating them to thereby select containers which contain a cultured solution that forms plaques in RK-13 cells but not in Vero E6 cells; and preparing a drug substance of vaccine using the aforementioned cultured solution (working seed solution), and a live smallpox vaccine prepared in the aforementioned process. | 2010-07-22 |
20100183673 | METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONS - Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided. | 2010-07-22 |
20100183674 | COMPOSITIONS COMPRISING YERSINIA PESTIS ANTIGENS - Disclosed are several | 2010-07-22 |
20100183675 | Stable vaccine compositions and methods of use - A stable lyophilized protein formulation containing recombinant Protective Antigen (rPA) is described that can be reconstituted with a suitable diluent to generate a high potency protein concentration reconstituted formulation which is suitable for use as a vaccine against anthrax infection in mammals, especially human beings. These formulations were prepared by lyophilizing rPA in the presence of a reducing sugar, such as trehalose, and methods of such lyophilization are described. The resulting lyophilized mixture or composition is subsequently reconstituted to high immunogenicity without apparent loss of stability of the rPA protein. Methods of using said formulations in vaccination are also described. | 2010-07-22 |
20100183676 | COMPOSITIONS COMPRISING OPA PROTEIN EPITOPES - The present invention relates to a composition comprising at least one purified Opa HV 1 protein epitope and at least one purified Opa HV2 protein epitope. The epitopes are preferably purified protein epitopes, preferably recombinant epitopes. The composition is preferably a pharmaceutical composition, more preferably a vaccine composition. The invention also relates to methods of immunisation and to specific formulations presented in the tables, and to novel nucleic acids encoding Opa alleles. | 2010-07-22 |
20100183677 | FUSION PROTEINS OF MYCOBACTERIUM TUBERCULOSIS - The present invention relates to compositions and fusion proteins containing at least two | 2010-07-22 |
20100183678 | CONJUGATES OF PLASMODIUM FALCIPARUM SURFACE PROTEINS AS MALARIA VACCINES - Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against | 2010-07-22 |
20100183679 | PRIMERS FOR DETECTING PLASMODIUM - The present invention provides an easy and rapid method for detecting/identifying the presence or absence of specific | 2010-07-22 |
20100183680 | Purified Plasmodium and Vaccine Compositions - Disclosed are substantially purified | 2010-07-22 |
20100183681 | METHOD OF TREATING ALLERGIES USING TGF-BETA1 AND ALLERGENS - The invention provides an allergy prevention method or treatment method, diets and oral drugs enabling prevention/treatment of allergic symptoms without trouble such as systemic adverse reaction, immune deficiency and the like caused by transdermal/intravenous administration of TGF-β. The allergy prevention method or treatment method is to orally administer 100 μg/kg or more of transforming growth factor-beta (TGF-β) relative to a weight of an administration target body and thereby selectively suppress Th2 immune response, while with respect to the diets and oral drugs, the content is set to contain an effective amount of transforming growth factor-beta (TGF-β) therein. | 2010-07-22 |
20100183682 | METHOD OF TREATING ALLERGIES USING TGF-BETA1 AND ALLERGENS - The invention provides an allergy prevention method or treatment method, diets and oral drugs enabling prevention/treatment of allergic symptoms without trouble such as systemic adverse reaction, immune deficiency and the like caused by transdermal/intravenous administration of TGF-β. The allergy prevention method or treatment method is to orally administer 100 μg/kg or more of transforming growth factor-beta (TGF-β) relative to a weight of an administration target body and thereby selectively suppress Th2 immune response, while with respect to the diets and oral drugs, the content is set to contain an effective amount of transforming growth factor-beta (TGF-β) therein. | 2010-07-22 |
20100183683 | CELL LINES, COMPOSITIONS COMPRISING THEM FOR THE TREATMENT OF MELANOMAS, PROCEDURES TO PREPARE THE COMPOSITIONS, AND TREATMENT METHODS - Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods. More particularly, the invention relates to diverse human melanoma cell lines for the treatment of malignant diseases, wherein the cell lines are: (a) Mel-XY1 (deposited at German Collection of Microorganisms and Cell Cultures DSMZ under access number DSM ACC2830), (b) Mel-XY2 (deposited at German Collection of Microorganisms and Cell Cultures DSMZ under access number DSM ACC2831), (c) Mel-XY3 (deposited at German Collection of Microorganisms and Cell Cultures DSMZ under access number DSM ACC2832), (d) Mel-XX4 (deposited at German Collection of Microorganisms and Cell Cultures DSMZ under access number DSM ACC2829), or (e) sub-populations thereof. The cell lines may be irradiated, thus obtaining populations with apoptotic phenotype, and populations with necrotic phenotype of such lines. The compositions may comprise adjuvants and/or immuno-modifiers, and/or autologous dendritic cells. | 2010-07-22 |
20100183684 | Oral vaccination - The invention relates to a drug for oral vaccination, the drug containing an anti-genically active substance and a gastric acid reducing substance as a combination preparation for joint or separate, simultaneous or time shifted, oral application for vaccination. | 2010-07-22 |
20100183685 | TUMOR AND INFECTIOUS DISEASE THERAPEUTIC COMPOSITIONS - A pharmaceutical composition comprising lectins is anti-tumorigenic and anti-viral, bacterial or protozoan. The composition, termed BiOmune is also useful for imaging, diagnosis and therapy of cancer. | 2010-07-22 |
20100183686 | Method to maintain the efficacy of Orlistat - A method to effectively treat the adverse events of ingested orlistat, and to maintain the effectiveness of ingested orlistat, the method comprising the steps of: ingesting a compound of orlistat to irreversibly bind with lipase enzymes of the gastrointestinal tract; ingesting a compound of simethicone to cause undigested fats to remain in an emulsified state in the bowel; and ingesting an enteric coated activated charcoal member to absorb emulsified fats only in the lower bowel, thus preventing the adverse events associated with the ingestion of orlistat alone. | 2010-07-22 |
20100183688 | Delivery System and Method of Manufacturing the Same - A microparticle delivery system for an active compound which includes an active compound loaded onto polymeric microparticles, wherein the loaded microparticles are encased by a matrix material comprising about 68% to about 99%, by weight, of the microparticle delivery system. Compositions containing the microparticle delivery system, and methods of manufacturing the microparticle delivery system, also are disclosed. | 2010-07-22 |
20100183689 | Making Method for Titania Nanoparticle - The present invention relates to a method of manufacturing titania nanoparticles, and specifically to a method of manufacturing titania nanoparticles wherein the particle size is uniform, it is possible to manufacture monodisperse particles without aggregation among particles, a uniform coating can be applied, that is suitable to large-scale production, and that can obtain high-resolution images by maintaining the toner electric charge and electric charge distribution; and the developer included in said titania nanoparticles. | 2010-07-22 |
20100183690 | Insect Repellent Textile - Disclosed embodiments include a textile with insect repellent properties comprising (a) a natural or synthetic fabric, (b) a microencapsulated active ingredient having insect repellent properties, and (c) a resin solution to attach said microencapsulated active ingredients to the fabric. According to a particular embodiment, and without limitation, the insect repellent textile uses a resin solution with a concentration designed to control the degree of wash fastness and gradual release of the microencapsulated active ingredient embedded in the textile in order for it to be gradually released by skin pressure and friction. A plurality of microencapsulated active ingredients could be used including microencapsulated permethrin or toluamide. | 2010-07-22 |
20100183691 | Use of Titanium metal fine-particles for increasing the effect of Germicidal medicines used for human skin dermatosis, skin infection and traumatism - The use of Titanium metal fine-particles for increasing of effect of the germicidal medicines used for human skin, skin infection and traumatism, is provided. The application of the Titanium metal fine-particles layer being laid on or close to skin, in combination with a medicine, functions to restrain bacteria breeding and multiplying, accelerate skin and dermic-organism metabolism, and promoting capillary purification. By these functions, an environment which is harmful and fatal for bacteria breeding/multiplying will be developed on the human body skin and dermic-organism. These functions are demonstrated by the increased effects of the germicidal medicines which are used for human skin dermatosis, skin infection and traumatism. | 2010-07-22 |
20100183692 | COMPOSITIONS - Provided are essentially preservative-free personal care product compositions that comprise a combination of fragrance compounds that stabilises the personal care product against microorganisms. The combination comprises certain benzaldehyde or benzaldehyde derivative compounds combined with certain fragrant acids. The composition is free of classical preservatives including parabens or their derivatives. Further provided are methods of forming such compositions and products and the use of the combination of fragrance compounds in such compositions and products. | 2010-07-22 |
20100183693 | Slow dissolving tablet composition for the in-situ generation of chlorine dioxide for use in a multi-tablet dispenser - A composition that generates and releases a biocidal solution comprising at least chlorine dioxide is presented. The composition comprises reactants capable of in-situ generation of chlorine dioxide, and a gelling agent that slows the rate of dissolution of the reactants, thereby increasing yield and providing a controlled release of biocidal solution. The compositions of the invention show improved environmental stability which can reduce the cost of packaging. The controlled release allows the use in multi-tablet chemical dispensers which may otherwise induce potentially explosive conditions or allow rapid release of the biocidal solution thereby inducing a spike in chemical concentration rather than a sustained release. | 2010-07-22 |
20100183695 | Cerberus/coco derivatives and uses thereof - The invention relates to Cerberus/Dan/Gremlin polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. Preferred polypeptides are Coco or Cerberus derivatives. | 2010-07-22 |
20100183696 | Treating Ocular Diseases Using Peroxisome Proliferator-Activated Receptor Delta Antagonists - The present invention provides novel agents, expression constructs, compositions and methods useful for treating an ocular disease associated with unwanted PPARδ activity through the modulation of PPARδ expression The PPARδ interference RNA (iRNA) agents, expression constructs encoding such agents, and compositions comprising such agents or constructs are directed against RNA molecules encoding PPARδ The methods comprise treating an ocular disease associated with unwanted PPARδ activity in a patient in need thereof by administering an effective amount of a pharmaceutical composition comprising a PPARδ iRNA agent or expression construct encoding such agent to the patient to reduce a symptom associated with unwanted PPARδ activity in the patient. | 2010-07-22 |
20100183697 | TISSUE-SEPARATING FATTY ACID ADHESION BARRIER - Exemplary embodiments of the present invention provide adhesion barriers having anti-adhesion and tissue fixating properties. The adhesion barriers are formed of fatty acid based films. The fatty acid-based films may be formed from fatty acid-derived biomaterials. The films may be coated with, or may include, tissue fixating materials to create the adhesion barrier. The adhesion barriers are well tolerated by the body, have anti-inflammation properties, fixate, well to tissue, and have a residence time sufficient to prevent post-surgical adhesions. | 2010-07-22 |
20100183698 | METHODS FOR PRODUCING BIOMATERIALS WITH VARIABLE STIFFNESS - This invention relates to the production of biomaterials with variable stiffness by subjecting a gel which varies in at least one dimension to plastic compaction. These biomaterials may be useful, for example, for the directional control or guidance of cells within tissue equivalent implants. | 2010-07-22 |
20100183699 | COMPOSITIONS AND METHODS TO CROSS LINK POLYMER FIBERS - Novel compositions comprising genipin for cross-linking polymer fibers, are provided. In aspects of the invention the compositions further comprise a solvent system, wherein said solvent system comprises alcohol solvent and water. The genipin-based compositions are useful in methods for promoting the stabilization of fibers in an aqueous environment, and in tissue engineering. The novel genipin-based composition is also useful in methods of treating dermatological conditions. | 2010-07-22 |
20100183700 | IMPLANTABLE PUMP FOR PROTEIN DELIVERY FOR OBESITY CONTROL BY DRUG INFUSION INTO THE BRAIN - Methods and compositions are provided for suppressing appetite by surgically implanting a drug infusion pump into a site in a subject, and delivering a stable suspension of an appetite suppressing agent a region in a central nervous system of the subject. The appetite suppressing agent binds to a target receptor on a neural cell in the central nervous system and modifies the receptor function to suppress appetite. | 2010-07-22 |
20100183701 | Wound Dressings comprising hydrated hydrogels and enzymes - A skin dressing comprises a hydrated hydrogel material including a source of lactate ions and a supply of glucose, optionally also including a source of zinc ions and a source of iodide ions. The dressing has beneficial effects on skin. | 2010-07-22 |
20100183702 | Therapies For Cancer Using RLIP76 - The present invention is a composition identified as a region of ralA binding protein 1, wherein the region neighbors a membrane-associated portion of the ralA binding protein 1, reduces transport activity and membrane association of the ralA binding protein 1 and kills cells undergoing uncontrolled cell growth in a subject that has cells undergoing uncontrolled cell growth. The region is used to generate medicines that kill malignant cells and tumorigenic cells. Medicines may be in the form of antibodies, si-RNA and small molecules that recognize the region. | 2010-07-22 |
20100183703 | PHARMACEUTICAL OR COSMETIC COMPOSITION CONTAINING A DOUBLE STRANDED RNA OLIGONUCLEOTIDE AND ITS USE AS AN ACTIVE PHARMACEUTICAL INGREDIENT IN THE TREATMENT OF ANDROGEN RELATED DISEASES - This invention refers to new double stranded oligonucleotides having specific antiandrogenic activity and particularly to their use in the treatment of androgen-related diseases. Oligonucleotides may preferably be formulated with an acceptable pharmaceutical support in pharmaceutical or cosmetic formulations which are related to androgen metabolism or aimed at providing a beneficial effect on skin and/or hair. | 2010-07-22 |
20100183704 | dsRNA FOR TREATING VIRAL INFECTION - The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the CAD target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes. The invention further includes methods for treating diseases caused by positive stranded RNA virus infection using the pharmaceutical compositions; and methods for inhibiting the propagation of positive stranded RNA viruses in and between cells. | 2010-07-22 |
20100183705 | PHOSPHOLIPID-ANALOGOUS COMPOUNDS - Phospholipid-analogous compounds of the general formula (I) | 2010-07-22 |
20100183706 | PEPTIDE EPITOPES OF APOLIPOPROTEIN B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies. | 2010-07-22 |
20100183707 | METHODS AND COMPOSITIONS FOR TREATING HIV INFECTION - A method for treating latent HIV infection is disclosed. The method includes administering to a subject in need of such treatment an effective amount of an anti-IκBα agent, an anti-IκBε agent or both; and administering to the subject an effective amount of an antiviral agent. A pharmaceutical composition for treating latent HIV infection is also disclosed. | 2010-07-22 |
20100183708 | Antigen Delivery Vectors and Constructs - The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals. | 2010-07-22 |
20100183709 | FORMULATION - The present invention relates to therapeutic formulations based on pumpkin products, in particular to encapsulated formulations for oral administration. A product of the invention comprises a hard gelatin capsule which encloses a unit dose of a formulation which comprises at least 50% by weight of one or more pumpkin product. | 2010-07-22 |
20100183710 | OMEPRAZOLE FORM B - A process for preparing pure omeprazole Form B, and compositions containing omeprazole Form B. | 2010-07-22 |
20100183711 | Pharmaceutical compositions for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis - The present invention provides methods for reducing Aβ deposition, Aβ neurotoxicity and microgliosis in an animal or human afflicted with a cerebral amyloidogenic disease, such as Alzheimer's disease (AD), by administering therapeutically effective amounts of the (R)-enantiomer of the dihydropyridine compound nilvadipine, also known as (−)-nilvadipine, to the animal or human. Further provided are methods for reducing the risk of Aβ deposition, Aβ neurotoxicity and microgliosis in animals or humans suffering from traumatic brain injury by administering (−)-nilvadipine after the traumatic brain injury and continuing treatment for a prescribed period of time thereafter. | 2010-07-22 |
20100183712 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to acylated indanyl amines according to the general formula (I) | 2010-07-22 |
20100183713 | GASTROINTESTINAL-SPECIFIC MULTIPLE DRUG RELEASE SYSTEM - The present invention provides compositions and methods for the multiple release of a drug in the gastrointestinal tract of a subject through the use of an oral multiple drug release system. The system provides site-specific release of the drug to both the small intestine and the colon in the form of multiple controlled doses for long-lasting efficacy, thereby reducing the drug dosing frequency. | 2010-07-22 |
20100183714 | GASTRORESISTANT PHARMACEUTICAL DOSAGE FORM COMPRISING N-(2-(2- PHTHALIMIDOETHOXY)-ACETYL)-L-ALANYL-D-GLUTAMIC ACID (LK-423) - The present invention relates to the pharmaceutical dosage forms which enable a controlled and/or a targeted delivery of an active substance to the selected regions of gastrointestinal tract of humans or animals. The pharmaceutical dosage forms preferably comprises the active substance N-(2(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (designated as LK 423). Methods of treatment of chronic inflammatory diseases of gastrointestinal tract of humans and/or animals by using the pharmaceutical dosage forms of the invention are disclosed. | 2010-07-22 |
20100183715 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR - Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV. | 2010-07-22 |
20100183716 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR - Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV. | 2010-07-22 |
20100183717 | CONTROLLED-RELEASE FORMULATIONS - Disclosed herein are controlled-release formulations of a core comprising a core active agent (e.g., alfuzosin) and a wax excipient substantially coated with an extended-release coating. | 2010-07-22 |
20100183718 | COMPOSITIONS AND TREATMENT OF HEART DEFICIENCY IN NON-HUMAN ANIMALS - The invention relates to novel compositions including an aldosterone antagonist and administered according to a predetermined dosage for treating heart deficiency in non-human mammals. | 2010-07-22 |
20100183719 | Surgical Applications for BMP Binding Protein - The present invention relates to the clinical application of BBP, alone or in combination with other growth factors, for use in bone healing applications, such as spinal surgery. Additional applications include use in orthopedic implantable prostheses and implantation into other surgical sites (e.g., surgical reconstruction, regional osteopenia, etc.) where bone is desired. | 2010-07-22 |
20100183720 | Hetero-assembled hydrogels - A two-component, molecular-recognition gelation strategy that enables cell encapsulation without the need for environmental triggers is provided. The two components, which in one example contain WW and polyproline-rich peptide domains that interact via hydrogen bonds, undergo a sol-gel phase transition upon simple mixing. Hence, physical gelation is induced by the mixing of two components at constant environmental conditions, analogous to the formation of chemically crosslinked epoxies by the mixing of two components. Variations in the molecular-level design of the two components are used to predictably tune the association energy and hydrogel viscoelasticity. These hetero-assembly physical hydrogels encapsulate neural progenitor cells at constant physiological conditions within 10 seconds to create uniform 3D cell suspensions that continue to proliferate, differentiate, and adopt well-spread morphologies. | 2010-07-22 |
20100183721 | ENHANCED DELIVERY OF IMMUNOSUPPRESSIVE DRUG COMPOSITIONS FOR PULMONARY DELIVERY - The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m | 2010-07-22 |
20100183722 | MODULATION OF PROTEASES. PARTICULARLY IN THE TREATMENT OF CHRONIC ULCEROUS SKIN LESIONS - The invention provides a method of modulating proteases, particularly when treating a wound (for example, a chronic ulcerous skin lesion) in a human or non-human mammal (particularly a human). The medium containing the proteases (e.g. the wound) is contacted with a topical hydrogel composition comprising a hydrophilic polymer carrying multiple pendant sulphonyl groups, optionally with multiple pendant carboxylic groups, on each polymer molecule. | 2010-07-22 |
20100183723 | Fetal Skin Cell Protein Compositions for the Treatment of Skin Conditions, Disorders or Diseases and Methods of Making and Using the Same - The present invention provides methods and compositions designed for treating a subject suffering from skin conditions, disorders or diseases. The compositions include fetal skin cell proteins obtained from fetal skin cells after induced cell lysis. | 2010-07-22 |
20100183724 | Hydrogel of Chitosan Carboxyalkylamide, Preparation Thereof and Cosmetic and Dermatological Use Thereof - The present invention relates to a hydrogel of chitosan carboxyalkylamide, characterised in that it has a pH value close to that of the skin, comprised between 6.5 and 7.2, and in that the chitosan carboxy-alkylamide is constituted by 40 to 90 mole % of D-glucosamine N-carboxyalkylamide units of formula (I) | 2010-07-22 |
20100183725 | MULTIPLE ACTIVE PHARMACEUTICAL INGREDIENTS COMBINED IN DISCRETE INHALATION PARTICLES AND FORMULATIONS THEREOF - The present disclosure describe inhalation particles where each discrete unagglomerated inhalation particle comprising 2 or more active pharmaceutical ingredients. In one embodiment, the inhalation particles comprise a first and a second API where the second API covers, at least partially, and protects the first API from degradation or instability. Inhalation particles comprising a first and a second API as described herein have many advantages over present means of delivering two or more APIs. Formulations comprising such inhalation particles are also described. | 2010-07-22 |
20100183726 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH DACARBAZINE NANOEMULSIONS - A uniform microfluidized nanoemulsion is disclosed containing an anti-cancer agent, such as dacarbazine. The microfluidized nanoemulsion improves the combination's cell membrane permeability by at least four-fold over conventional nanoemulsion compositions, which significantly increases the intracellular concentration of anti-cancer agents. As a nanoemulsion, dacarbazine has a greater anti-cancer efficacy than when applied as a free solution. | 2010-07-22 |
20100183727 | Immunonanotherapeutics that Provide IgG Humoral Response Without T-Cell Antigen - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides synthetic nanocarriers capable of eliciting an immune system response in the form of antibody production, wherein the nanocarriers lack any T cell antigens. In some embodiments, the invention provides nanocarriers that comprise an immunofeature surface, which provides high avidity binding of the nanocarriers to antigen presenting cells. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof. | 2010-07-22 |
20100183728 | NANOPARTICLE COMPRISING RAPAMYCIN AND ALBUMIN AS ANTICANCER AGENT - The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy. | 2010-07-22 |
20100183729 | Novel Process - The invention relates to a stable pharmaceutical composition useful in the treatment of respiratory disorders such as asthma, rhinitis and chronic obstructive pulmonary disease (COPD) and a novel micronisation process for manufacturing a stable formulation for formoterol or its enantiomers and a carrier/diluent comprising a carbohydrate such as lactose. | 2010-07-22 |
20100183730 | High dose composition of ursodeoxycholic acid - The present invention relates to high dose multiparticulate pharmaceutical formulation comprising ursodeoxycholic acid for oral administration, as well as a method for preparing said composition. | 2010-07-22 |
20100183731 | NANOPARTICLES COMPRISING DRUG, A NON-IONIZABLE CELLULOSIC POLYMER AND TOCOPHERYL POLYETHYLENE GLOCOL SUCCINATE - A pharmaceutical composition comprises nanoparticles comprising a poorly water soluble drug, a non-ionizable cellulosic polymer, and TPGS. | 2010-07-22 |
20100183732 | Novel one step process for preparing cross-linked poly(allylamine) polymers - The present invention relates to a novel one step process for preparing cross-linked poly(allylamine) polymers or salts thereof using the novel cross-linking agent of Formula (IV). This invention also relates to the compound of Formula (IV) as well as to a process to obtain it. The cross-linked poly(allylamine) polymers of the invention are useful in medicine as substrate-binding polymers. | 2010-07-22 |
20100183733 | HAIR GROWTH-INHIBITING AGENT - A hair removing agent or a hair growth inhibiting agent is provided by determining an endogenous factor having a hair growth inhibitory activity, screening for substances having an activity similar to that of the endogenous factor or substances enhancing the activity or expression of the endogenous factor, and utilizing the physiological activities of such substances. It has been found that FGF18 inhibits hair growth. A method of screening for FGF18-like active substances, substances that promote the activity of FGF18 or substances that promote the expression of FGF18 to thereby obtain candidates for the hair growth inhibiting agent or hair removing agent is disclosed. Also disclosed is a hair growth inhibiting agent or a hair removing agent comprising, as an active ingredient, FGF18 and/or an FGF18 partial peptide, or an FGF18-like active substance and/or a substance that promotes the activity or expression of FGF18 (e.g., Digenea simplex extract). | 2010-07-22 |
20100183734 | Influence of genotype on susceptibility to treatment with fish oil - The present invention relates to methods for assessing an individual's susceptibility to treatment of an inflammatory disease with a dietary supplement. The invention describes the recognition that the sensitivity of an individual to the inflammation suppressing effects of fish oil on TNF-a production is linked both to genetic variation encoded by, or associated with, TNF-a and/or IL-6 single nucleotide polymorphisms and to the inherent level of production of TNF-a by cells. | 2010-07-22 |
20100183735 | METHOD FOR INDUCING SELECTIVELY SUPPRESSED IMMUNE RESPONSE TO TRANSPLANTED TISSUE OR CELLS - Transimmunization methods incorporating skin immunologic challenges are described for either selectively suppressing the immune response of recipients of transplanted tissue or cells or monitoring induced anti-cancer immunity. In one embodiment, skin from the transplant donor is allografted to the transplant recipient to induce an immunological response to the transplanted skin. A quantity of blood is taken from the recipient and treated to render the T cells in the blood apoptotic and to induce differentiation of blood monocytes into dendritic cells. The treated blood is incubated and administered to the recipient to induce formation of suppressor T cell clones which reduce the number of T cells attacking the transplanted tissue or organ. This tolerogenic approach can be complemented by also feeding the immature dendritic cells apoptotic or necrotic cells from the organ donor. In a second embodiment, dendritic cells loaded with tumor antigens are injected intradermally to monitor the anti-cancer immunity induced by Transimmunization. | 2010-07-22 |
20100183736 | REHYDRATION BEVERAGE - The present invention relates to a composition for the relief of hangover symptoms and methods of treating hangover symptoms. | 2010-07-22 |
20100183737 | GLASS FLAKE - The glass flake of the present invention has a composition that includes, in terms of mass %, 602010-07-22 | |
20100183738 | METHOD AND COMPOSITION FOR INHIBITING GROWTH OF MICROORGANISMS IN INDUSTRIAL PROCESS WATERS IN THE PRESENCE OF ANIONIC ANTI-FOULING ADDITIVES - A composition and method for treating industrial water is described, wherein the composition has microbe inhibiting properties. The composition utilizes a cationic phase transfer agent, such as a quaternary ammonium compound in the presence of a peroxide source. The composition does not significantly reduce the anti-scaling properties of anionic dispersants present in the water. | 2010-07-22 |
20100183739 | Treatment and prevention of systemic bacterial infections in plants using antimicrobial metal compositions - An embodiment of the invention is a treatment for the mitigation and prevention of systemic infection of plants using materials derived from bactericidal metals wherein one metal is silver. The candidate bactericidal metal is preferably introduced in metallic, nanocrystalline, salt form, chelated form, or otherwise coupled form. Metal atoms, ions, molecules, clusters, or particles in concentrations between 0.001 to 100,000 parts per million (ppm) may be employed, wherein the preferred concentration of silver is sufficient to suppress bacterial viability. The bactericidal principle is preferably introduced to the plant by injection, ballistic insertion, pneumatic insertion, mechanical insertion, manual insertion, root application, aerosolization or spray in order to effect the treatment and prevention of systemic plant infections by bacterial agents of disease or reduced productivity. | 2010-07-22 |
20100183740 | Potent Inhibitory Effect of Zinc in Combination with Sulforaphane on Cancer Cell Growth - This invention relates to compositions comprising zinc and sulforaphane which can be used in the treatment or prevention of cancer. The invention also relates to methods of treating or preventing cancer, including prostate cancer, which comprises the administration of zinc and sulforaphane to a patient in need thereof. | 2010-07-22 |
20100183741 | DERMATOLOGICAL COMPOSITIONS COMPRISING AT LEAST ONE RETINOID COMPOUND, AN ANTI-IRRITANT COMPOUND AND BENZOYL PEROXIDE - Dermatological compositions contain, formulated into a physiologically acceptable medium, at least one retinoid compound selected from among all-trans retinoic acid, isotretinoin, motretinide, and naphthoic acid compounds of formula (I), and salts and esters thereof: | 2010-07-22 |
20100183742 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS FOR THE TREATMENT OF CANCER - Compositions containing, and, methods administering, TH302, are useful in treatment of cancer and other hyper-proliferative diseases. | 2010-07-22 |
20100183743 | BENZTHIAZOLE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE - Inhibitors of poly(ADP-ribose)polymerase having a structure of Formula (I), ways to make them and methods of treating patients using them are disclosed. | 2010-07-22 |
20100183744 | Systems and methods for maintaining the dominance of nannochloropsis in an algae cultivation system - Systems and methods for maintaining the dominance of | 2010-07-22 |
20100183745 | Electrochemical Device for Biocide Treatment in Agricultural Applications - The invention relates to an electrochemical device which simultaneously carries out the production of an oxidising solution at controlled composition containing hypochlorous acid and the sprinkling thereof in a continuous process, useful for biocide treatments in agricultural fields. The device can be installed on motor vehicles or mobile means in general. | 2010-07-22 |
20100183746 | BIOCIDES AND APPARATUS - A biocide is formed by mixing at least one of ammonium sulfamate and ammonium carbamate with an aqueous solution of a hypochlorite oxidant at a molar ratio of ammonium to hypochlorite of at least 1:1. The biocide is useful in treating microbial or biofilm growth, pulp and paper process water, cooling tower water, waste water, reclaimed waste water, sludge, colloidal suspensions, irrigation water or a medium having a reducing capacity. | 2010-07-22 |
20100183747 | BODY FLUID EXPANDERS COMPRISING N-SUBSTITUTED AMINOSULFONIC ACID BUFFERS - A buffered body fluid expander solution, in which the buffer is a physiologically acceptable buffer that is not an inorganic phosphate buffer, comprises calcium ions and magnesium ions at a concentration ratio of 5:1 to 1:1. The non-phosphate buffer may be a physiologically acceptable N-substituted aminosulfonic acid buffers, especially those having a pKa value in aqueous solution of from 7.1 to 7.5 at 2O0C, and most preferably N-tris(hydroxymethyl) methyl-2-aminoethanesulfonic acid (TES), 3-(N-morpholino) propanesulfonic acid (MOPS), N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES) and combinations thereof. Preferred components include from 100 to 150 (preferably about 135) mmoles/L sodium ions, from 2.5 to 6.2 (preferably about 5) mmoles/L potassium ions, from 0.1 to 2.5 (preferably about 1.25) mmoles/L calcium ions, from 0.4 to 25.0 (preferably about 0.45) mmoles/L magnesium ions, from 96 to 126 (preferably about 118) mmoles/L chloride ions, 2 to 11 mmoles/L (preferably about 10) glucose (preferably D-glucose), from 50 to 150 (preferably about 110) μmoles/L glycerol, from 7 to 15 (preferably about 10) μmoles/L choline, from 5 to 400 (preferably about 300) μmoles/L glutamate (preferably L-glutamate), from 5 to 200 (preferably about 20) μmoles/L aspartate (preferably L-aspartate), from 100 to 2000 (preferably about 400) μmoles/L glutamine (preferably L-glutamine), from 15 to 215 (preferably about 60) μmoles/L pyroglutamate, from 20 to 200 (preferably about 100) μmoles/L arginine (preferably L-arginine), from 1 to 120 (preferably about 40) nmoles/L thiamine pyrophosphate (TPP), from 40 to 70 (preferably about 50) μmoles/L D- or DL or L-carnitine (preferably L-carnitine), and from 5 to 200 (preferably about 28) ml.U./L porcine or human insulin (preferably human insulin). The solutions are useful for the manufacture of medicaments and blood volume expanders, for treating hypovolemia or for treating the loss of extracellular and interstitial fluid in subjects suffering with burns, for treating respiratory and/or metabolic acidosis in a subject, for perfusion of the abdominal cavity during peritoneal dialysis of a subject with acute renal failure or an acute toxicity condition, for preventing and/or ameliorating reperfusion injury, and for delivering a therapeutic, test and/or synergistic agent to a subject, including a biological agent, such as at least one stem cell, peptide or genomic derived protein. | 2010-07-22 |
20100183748 | Methods for Treating or Preventing Radiocontrast Agent Induced Kidney Injury - Methods for treating or preventing radiocontrast agent induced kidney injury in a mammal are disclosed, the methods comprising administering to the mammal a first effective amount of a chalcogenide composition prior to administering a radiocontrast agent to the mammal. | 2010-07-22 |
20100183749 | TOPICALLY ACTIVE STEROIDS FOR USE IN RADIATION AND CHEMOTHERAPEUTICS INJURY - The present invention features methods of delivering corticosteroids or metabolites thereof for treating and preventing tissue damage resulting from acute radiation injury in the gastrointestinal tract with locally effective therapeutic agents. | 2010-07-22 |
20100183750 | FORTIFICATION OF PLANTS WITH FOLATES BY METABOLIC ENGINEERING - The invention relates to a transgenic plant overexpressing a polynucleotide encoding a plant GTP cyclohydrolase I (GTPCHI) enzyme. The present invention also relates to a product comprising the transgenic plant of the invention or a harvestable part, plant organ, plant tissue, plant cell, seed, or a propagule of said plant. The present invention further elucidate the use of the plant of the invention to cross breed with other plants, as biofortification to enrich the quality of the food intake of an animal or human subject, for the manufacture of a medicament to prevent folate insufficiency, or, for the treatment of folate insufficiency or diseases or disorders resulting from said insufficiency in an animal or human subject. | 2010-07-22 |
20100183752 | Foamable Compositions - A propellant-free foamable transparent composition, foamable by mixing with air or by hand rubbing, comprises a water-immiscible oil composition comprising at least one water-immiscible oil, which may be a mineral oil or vegetable oil, a siloxane resin foam stabiliser which is miscible in the water-immiscible oil composition to form a transparent liquid, and potentially a siloxane resin solubilising agent. The composition may be used for cosmetic applications. | 2010-07-22 |
20100183753 | NEMATODE CONTROL AGENT - A composition for the control of nematodes consisting of salicylaldehyde and a surfactant. Garlic extract added to the salicylaldehyde provides a composition that demonstrates a more potent control action against potato cyst nematodes. | 2010-07-22 |
20100183754 | Extract and compound for blood pressure regulation - The present invention provides an extract of Taiwanese wild grape ( | 2010-07-22 |
20100183755 | BLOAT CONTROLLING AGENT FOR A RUMINANT - The present invention provides a bloat controlling agent for a ruminant, comprising cashew nut shell liquid. | 2010-07-22 |
20100183756 | RUMEN FERMENTATION IMPROVING AGENT - The present invention provides a rumen fermentation improving agent, comprising cashew nut shell liquid. | 2010-07-22 |
20100183757 | DIE PRESS ASSEMBLY FOR POWDER PRESSING - A die press assembly ( | 2010-07-22 |
20100183758 | ACTUATOR FOR DEEP-DRAW THERMOSHAPING MACHINE - A thermoshaping machine has a movable die operated by a linkage and an actuator having a transmission fixed on the machine, operatively connected to the linkage, and having a transmission flange. A motor has a motor flange spaced along an axis from the transmission flange. The flanges are each formed centered on the axis with a respective circular array of holes, and each hole of the transmission flange is aligned axially with a respective hole of the transmission flange. Respective guide rods have outer ends fixed in the holes of one of the flanges and inner ends extending axially through the holes of the other flange. Respective elastically compressible biasing elements are braced axially between each of the inner ends and the other flange. | 2010-07-22 |
20100183759 | Roller for Pelleting Mill - A pellet mill includes a die carrying material to be extruded into pellets. The die rotates to bring the material toward rollers within the die. The rollers push the material through extrusion holes in the die. The rollers are mounted on and rotate about support shafts that are held stationary within the die. Sealing devices at the ends of the rollers prevent foreign material from interfering with bearings between the rollers and the support shafts. Each of the sealing devices include one or more sealing elements. The sealing elements may include a pair of mating grooves and protrusions. | 2010-07-22 |
20100183760 | MANUFACTURING MICRO-STRUCTURED ELEMENTS - According to the invention, a micro-structured element is manufactured by replicating/shaping (molding or embossing or the like) a 3D-structure in a preliminary product using an replication tool ( | 2010-07-22 |
20100183761 | MOLD FOR THERMOPLASTIC RESIN MOLDING, CAVITY MOLD, AND PROCESS FOR PRODUCING THE CAVITY MOLD - A process for producing a heat-insulating cavity mold, characterized by producing two members, i.e., a metallic surface layer member ( | 2010-07-22 |
20100183762 | Sealing Arrangement for an Edge Gated Nozzle in an Injection Molding System - An injection molding apparatus having a sealing arrangement between a hot runner manifold and edge-gated nozzle that accommodates thermal expansion during operation is disclosed. A spacer element is axially fixed in position between the manifold and a mold plate in which the nozzle sits. The nozzle includes a reduced diameter spigot portion on an upstream end that is in a telescopic/slidable relationship with a bore of the spacer element. The nozzle includes radially extended nozzle tips axially fixed in position at a downstream end of the nozzle that are in fluid communication with respective mold gates and corresponding mold cavities. In the cold condition, a gap G exists between a shoulder of the nozzle proximate the spigot portion and a corresponding surface of the spacer element bore. Under operating conditions, thermal expansion of the nozzle is accommodated in a direction of the manifold by the gap. | 2010-07-22 |